LJN 452

Drug Profile

LJN 452

Alternative Names: LJN452

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary bile acid malabsorption; Primary biliary cirrhosis

Most Recent Events

  • 20 Oct 2017 Pharmacodynamics data from preclinical studies in Non alcoholic steatohepatitis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 18 Apr 2017 Allergan in collaboration with Novartis plans a phase IIb trial for Non-alcoholic steatohepatitis (Combination therapy)
  • 27 Mar 2017 Novartis plans regulatory filings for Non-alcoholic steatohepatitis in 2021
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top